A selection of peer-reviewed papers, a book chapter, and invited talks from across my career in complex drug product development.

Highlights

Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466 — Communications Biology, 2021

Predicting bioavailability of monoclonal antibodies after subcutaneous administration — Advanced Drug Delivery Reviews, 2020

Novel application of synchrotron x-ray computed tomography for subcutaneous formulations — Pharmaceutical Research, 2020

Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466

Communications Biology, 2021 — cited over 100 times.

View all publications

Journal Articles & Book Chapters

Year	Title and Authors	Link
2025	Advances in nasal biopharmaceutics to support product development and therapeutic needs. B Forbes, L Goodacre, AB Lansley, AR Martin, H Palmer, C Patterson, et al.	Pharmaceutics 17(10), 1321
2023	In depth characterization of physicochemical critical quality attributes of a clinical drug-dendrimer conjugate. S Sonzini, F Caputo, D Mehn, … C Patterson [12th of 15] … N Akhtar	International Journal of Pharmaceutics 637, 122905
2023	The global characterisation of a drug-dendrimer conjugate – PEGylated poly-lysine dendrimer. N Akhtar, MB Ashford, … C Patterson [24th of 32] … S Wren	Journal of Pharmaceutical Sciences 112(3), 844-858
2022	Determining bioequivalence possibilities of long acting injectables through population PK modelling. P Gajjar, J Dickinson, H Dickinson, L Ruston, HB Mistry, C Patterson, PA Dickinson	European Journal of Pharmaceutical Sciences 179, 106296
2022	Population PK modelling as an alternative route to bioequivalence. P Gajjar, J Dickinson, H Dickinson, L Ruston, HB Mistry, C Patterson, PA Dickinson	British Journal of Pharmacy 7(2), S1-S2
2022	Biopharmaceutics of Injectable Formulations. WW Lee, CM Patterson	Chapter in Biopharmaceutics: From Fundamentals to Industrial Practice, pp. 253–263
2021	Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy. CM Patterson, SB Balachander, I Grant, P Pop-Damkov, B Kelly, et al.	Communications Biology 4, 112
2020	Predicting bioavailability of monoclonal antibodies after subcutaneous administration: open innovation challenge. M Sánchez-Félix, M Burke, HH Chen, C Patterson, S Mittal	Advanced Drug Delivery Reviews 167, 66–77
2020	IMI – Oral biopharmaceutics tools project – Evaluation of bottom-up PBPK prediction success part 4: prediction accuracy and software comparisons with improved data and modelling strategies. A Ahmad, X Pepin, … C Patterson [9th of 69] … A Rostami-Hodjegan	European Journal of Pharmaceutics and Biopharmaceutics 156, 50–63
2020	Novel application of synchrotron x-ray computed tomography for ex-vivo imaging of subcutaneously injected polymeric microsphere suspension formulations. C Patterson, D Murphy, S Irvine, L Connor, Z Rattray	Pharmaceutical Research 37(6), 97
2018	Nonclinical safety and pharmacokinetics of Miglyol 812: a medium chain triglyceride in exenatide once weekly suspension. N Buss, P Ryan, T Baughman, D Roy, C Patterson, C Gordon, R Dixit	Journal of Applied Toxicology 38(10), 1293–1301
2012	An investigation into the utility of a multi-compartmental, dynamic system of the upper gastrointestinal tract to support formulation development and establish bioequivalence of poorly soluble drugs. PA Dickinson, R Abu Rmaileh, L Ashworth, RA Barker, WM Burke, C Patterson, N Stainforth, M Yasin	The AAPS Journal 14(2), 196–205
2007	An investigation into the influence of drug lipophilicity on the in vivo absorption profiles from subcutaneous microspheres and in situ forming depots. CM Deadman, IW Kellaway, M Yasin, PA Dickinson, S Murdan	Journal of Controlled Release 122(1), 79–85 (published as C.M. Deadman)
2006	Biopharmaceutical studies of slow release, subcutaneous polymeric drug delivery systems CM Deadman	Doctoral thesis, PQDT-Global (published as C.M. Deadman) Link: none available

Selected Presentations & Panels

Year	Title	Event
2025	Panel session chair: “Small Fish, Big Trials: Boosting Value, Cutting Costs, and Winning Investors”	Bio Integrates, Cambridge
2025	Invited presentation: Formulation Approaches for Drug Delivery to the CNS	Transforming Therapeutic Delivery to the CNS: Challenges and Innovation hosted by Medicines Discovery Catapult
2023	Podium presentation: “Nanomedicine Formulation: from bench to bedside”	APS PharmSci, Reading
2023	Podium presentation and panelist: Translational Nanomedicine	Nanomed Europe, ELRIG satellite event
2023	Panelist: “Formulation – What’s new and do I need to be there?”	BioIntegrates, London
2022	Podium presentation and panelist: “Physiologically based biopharmaceutics modelling for nasal delivery”	Drug Delivery to the Lung, APS pre conference workshop: “Nasal Biopharmaceutics: fit for current and future drug delivery needs?”, Edinburgh
2022	Panelist: “Get out(sourced)”	BioIntegrates, London
2021	Invited speaker: “Formulating Complex Medicines: A simple solution?”	MDC Connects Series: “Complex Medicines: Ready for the Clinic/Scaling up for Success”
2019	Invited presentation: “Industrial Perspectives on Nanomedicine Development”	5th Annual Formulation and Drug Delivery Congress, London
2018	Invited keynote speaker: “Pharmaceutical Development of Nanomedicines: An Industrial Perspective”	European Technology Platform on Nanomedicine, Berlin

Position Papers & Industry Reports

Year	Title and Authors	Published
2025	Model-Informed Design of Oral Controlled Release Products in Early Proof-of-Concept Studies C Patterson	Pharma Services Hub Technical Insight Series
2024	Preparation, characterisation and in vitro assessment of siRNA-loaded lipid-based nanoparticles. F Joubert, N Ponnappan, L Toms, C Patterson, L FitzPatrick	Medicines Discovery Catapult
2021	Proposed definition of “complex medicine”: identifying technologies requiring innovation and support. C Patterson	Medicines Discovery Catapult

A complete, continually updated publication record is available on Google Scholar.